Edition:
United States

Cyclacel Pharmaceuticals Inc (CYCCP.OQ)

CYCCP.OQ on NASDAQ Stock Exchange Capital Market

7.00USD
26 Sep 2016
Change (% chg)

-- (--)
Prev Close
$7.00
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
479
52-wk High
$10.30
52-wk Low
$3.60

CYCCP.OQ

Chart for CYCCP.OQ

About

Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor... (more)

Overall

Beta: 3.18
Market Cap(Mil.): $22.64
Shares Outstanding(Mil.): 3.77
Dividend: --
Yield (%): --

Financials

  CYCCP.OQ Industry Sector
P/E (TTM): -- 44.84 37.54
EPS (TTM): -4.18 -- --
ROI: -64.29 -0.27 13.98
ROE: -65.97 -2.93 14.88

BRIEF-Tang Capital reports 9.5 pct stake in Cyclacel Pharmaceuticals

Source text - http://bit.ly/2cDs1vi Further company coverage:

Sep 16 2016

BRIEF-Intra-Cellular Therapies files for mixed shelf of up to $350 mln

* Files for mixed shelf of up to $350 million - SEC filing Source: (http://bit.ly/2c1aXOy) Further company coverage:

Sep 02 2016

BRIEF-Intra-Cellular Therapies reported Q2 EPS ($0.71)

* Cellular Therapies reports second quarter 2016 financial results and provides corporate update

Aug 04 2016

BRIEF-Cyclacel Pharmaceuticals may issue, sell shares having aggregate offering price of up to $4 mln through FBR

* Sales agreement with FBR Capital Markets & Co; may issue, sell shares having aggregate offering price of up to $4 million through FBR Source text: http://1.usa.gov/28Qcw2y Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Jun 23 2016

BRIEF-Cyclacel Pharmaceuticals files for mixed shelf of up to $100 mln - SEC filing

* Files for mixed shelf of up to $100 million - sec filing Source: (http://1.usa.gov/1WIQTTw ) Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Jun 10 2016

BRIEF-Cyclacel Pharmaceuticals announces reverse stock split

* Cyclacel announces reverse stock split Source text for Eikon: Further company coverage: (Bengaluru Newsroom +1-646-223-8780)

May 27 2016

BRIEF-Cyclacel Pharmaceuticals files for mixed shelf of up to $53.6 mln - SEC Filing

* Files for mixed shelf of up to $53.6 million - sec filing Source text (http://1.usa.gov/1pQ9azJ) Further company coverage: (Bengaluru Newsroom; +1 646 223 8780; )

Apr 29 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : New Constructs, LLC
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : S&P Capital IQ Quantitative Report
$127.00
Provider : Pechala's Reports
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.